Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies

Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies Abstract Urological malignancies, represented mainly by prostate, bladder, and renal cancers, are some of the leading causes of cancer-related mortalities worldwide. Despite various efforts over decades to develop early detection tests and effective therapeutic paradigms, the response rate to the existing treatments remains low for both primary and late stage/recurrent phases of these cancers. The evolving landscape of molecular diagnostics, aiming to make the diagnosis and treatment more patient-driven, underpins precision oncology and particularly intends to rationally profile individual tumors and highlight the mechanistic insight and complexity of tumor microenvironment in order to develop biomarkers of toxicity risks and response prediction in a clinically oriented dynamical setting. The present review is an effort to capture some of the recent developments in the area of molecular diagnostics and functional testing platforms and their potential application in clinical decision making in the premises of precision oncology of urological malignancies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Indian Journal of Surgical Oncology Springer Journals

Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/molecular-and-functional-diagnostic-tools-in-precision-oncology-for-974puu3GoL
Publisher
Springer Journals
Copyright
2016 Indian Association of Surgical Oncology
ISSN
0975-7651
eISSN
0976-6952
DOI
10.1007/s13193-016-0591-4
Publisher site
See Article on Publisher Site

Abstract

Abstract Urological malignancies, represented mainly by prostate, bladder, and renal cancers, are some of the leading causes of cancer-related mortalities worldwide. Despite various efforts over decades to develop early detection tests and effective therapeutic paradigms, the response rate to the existing treatments remains low for both primary and late stage/recurrent phases of these cancers. The evolving landscape of molecular diagnostics, aiming to make the diagnosis and treatment more patient-driven, underpins precision oncology and particularly intends to rationally profile individual tumors and highlight the mechanistic insight and complexity of tumor microenvironment in order to develop biomarkers of toxicity risks and response prediction in a clinically oriented dynamical setting. The present review is an effort to capture some of the recent developments in the area of molecular diagnostics and functional testing platforms and their potential application in clinical decision making in the premises of precision oncology of urological malignancies.

Journal

Indian Journal of Surgical Oncology – Springer Journals

Published: Mar 1, 2017

Keywords: surgical oncology; oncology; surgery

References

  • Evaluation of prostate cancer characteristics in four populations worldwide
    CM Zeigler-Johnson, H Rennert, RD Mittal, M Jalloh, R Sachdeva, SB Malkowicz
  • The health economics of bladder cancer: a comprehensive review of the published literature
    MF Botteman, CL Pashos, A Redaelli, B Laskin, R Hauser
  • Screening for prostate cancer: U.S. preventive services task force recommendation statement
    VA Moyer
  • Biomarkers in prostate cancer surveillance and screening: past, present, and future
    KC Cary, MR Cooperberg
  • Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer
    MJ Barry
  • Role of the TMPRSS2-ERG gene fusion in prostate cancer
    SA Tomlins, B Laxman, S Varambally, X Cao, J Yu, BE Helgeson
  • Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests
    S Goodison, CJ Rosser, V Urquidi
  • Cancer genome landscapes
    B Vogelstein, N Papadopoulos, VE Velculescu, S Zhou, LA Diaz, KW Kinzler
  • Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin
    KA Hoadley, C Yau, DM Wolf, AD Cherniack, D Tamborero, S Ng
  • Molecular subclassification of kidney tumors and the discovery of new diagnostic markers
    M Takahashi, XJ Yang, J Sugimura, J Backdahl, M Tretiakova, CN Qian
  • The evolutionary history of lethal metastatic prostate cancer
    G Gundem, P Van Loo, B Kremeyer, LB Alexandrov, JM Tubio, E Papaemmanuil
  • A molecular signature predictive of indolent prostate cancer
    S Irshad, M Bansal, M Castillo-Martin, T Zheng, A Aytes, S Wenske
  • A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling
    EA Klein, MR Cooperberg, C Magi-Galluzzi, JP Simko, SM Falzarano, T Maddala
  • Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy
    N Erho, A Crisan, IA Vergara, AP Mitra, M Ghadessi, C Buerki
  • Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy
    JT Bishoff, SJ Freedland, L Gerber, P Tennstedt, J Reid, W Welbourn
  • What is the need for prostatic biomarkers in prostate cancer management?
    M Spahn, S Boxler, S Joniau, M Moschini, B Tombal, RJ Karnes
  • Screening and monitoring for bladder cancer: refining the use of NMP22
    LE Ponsky, S Sharma, L Pandrangi, S Kedia, D Nelson, A Agarwal
  • Usefulness of the BTA STAT test for the diagnosis of bladder cancer
    JL Gutierrez Banos, M Henar Rebollo Rodrigo, FM Antolin Juarez, BM Garcia
  • Diagnostic utility of the ImmunoCyt/uCyt+ test in bladder cancer
    KL Greene, A Berry, BR Konety
  • ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study
    HX Li, M Li, CL Li, JH Ma, MR Wang, J Rao
  • Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice
    J Laudadio, TE Keane, HM Reeves, SJ Savage, RS Hoda, JM Lage
  • Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy
    AJ Stephenson, A Smith, MW Kattan, J Satagopan, VE Reuter, PT Scardino
  • Molecular diagnostics in urologic malignancies: a work in progress
    GJ Netto
  • Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer
    J Schalken, S Dijkstra, E Baskin-Bey, I Oort
  • Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer
    TJ Mackey, A Borkowski, P Amin, SC Jacobs, N Kyprianou
  • Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer
    M Atkins, M Regan, D McDermott, J Mier, E Stanbridge, A Youmans
  • Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer
    M Kohli, CY Young, DJ Tindall, D Nandy, KM McKenzie, GH Bevan
  • Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy
    C Ibeawuchi, H Schmidt, R Voss, U Titze, M Abbas, J Neumann
  • Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer
    GV Thomas, S Horvath, BL Smith, K Crosby, LA Lebel, M Schrage
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki
  • Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy
    G Ploussard, S Terry, P Maille, Y Allory, N Sirab, L Kheuang
  • Oncogenic HRAS activates epithelial-to-mesenchymal transition and confers stemness to p53-deficient urothelial cells to drive muscle invasion of basal subtype carcinomas
    F He, J Melamed, MS Tang, C Huang, XR Wu
  • 'Toxgnostics': an unmet need in cancer medicine
    D Church, R Kerr, E Domingo, D Rosmarin, C Palles, K Maskell
  • Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity
    JP Svensson, LJ Stalpers, RE Esveldt-van Lange, NA Franken, J Haveman, B Klein
  • Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radio-resistance: a pilot study in prostate cancer patients receiving radiotherapy
    J Hummerich, G Werle-Schneider, O Popanda, O Celebi, J Chang-Claude, S Kropp
  • Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
    J Garcia-Donas, E Esteban, LJ Leandro-Garcia, DE Castellano, AG Alba, MA Climent
  • Review: side effects of approved molecular targeted therapies in solid cancers
    C Widakowich, G Castro, E Azambuja, P Dinh, A Awada
  • Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
    J Ciccolini, E Gross, L Dahan, B Lacarelle, C Mercier
  • Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients
    EA Calhoun, CH Chang, EE Welshman, DA Fishman, JR Lurain, CL Bennett
  • Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient
    T Yoshida, H Kinoshita, T Segawa, E Nakamura, T Inoue, Y Shimizu
  • Structural basis for antagonism and resistance of bicalutamide in prostate cancer
    CE Bohl, W Gao, DD Miller, CE Bell, JT Dalton
  • Functional characterization of mutant androgen receptors from androgen-independent prostate cancer
    MA Fenton, TD Shuster, AM Fertig, ME Taplin, G Kolvenbag, GJ Bubley
  • Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design
    CE Bohl, Z Wu, DD Miller, CE Bell, JT Dalton
  • Detecting predictive androgen receptor modifications in circulating prostate cancer cells
    Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C,
  • MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers
    BL Jackson, A Grabowska, HL Ratan
  • A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
    SV Sharma, DY Lee, B Li, MP Quinlan, F Takahashi, S Maheswaran
  • Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition
    A Goldman, B Majumder, A Dhawan, S Ravi, D Goldman, M Kohandel
  • Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
    B Majumder, U Baraneedharan, S Thiyagarajan, P Radhakrishnan, H Narasimhan, M Dhandapani
  • Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma
    EM Van Allen, VW Lui, AM Egloff, EM Goetz, H Li, JT Johnson
  • Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma
    S Peters, O Michielin, S Zimmermann
  • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
    F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss
  • Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors
    D Ercan, C Xu, M Yanagita, CS Monast, CA Pratilas, J Montero
  • Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
    M Gerlinger, S Horswell, J Larkin, AJ Rowan, MP Salm, I Varela
  • Spatial genomic heterogeneity within localized, multifocal prostate cancer
    PC Boutros, M Fraser, NJ Harding, R Borja, D Trudel, E Lalonde
  • Influence of tumour micro-environment heterogeneity on therapeutic response
    MR Junttila, FJ Sauvage
  • Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract
    KB Collins, BK Patterson, GJ Naus, DV Landers, P Gupta
  • Spherical cancer models in tumor biology
    LB Weiswald, D Bellet, V Dangles-Marie
  • Three-dimensional organotypic culture: experimental models of mammalian biology and disease
    ER Shamir, AJ Ewald
  • Identification of selective inhibitors of cancer stem cells by high-throughput screening
    PB Gupta, TT Onder, G Jiang, K Tao, C Kuperwasser, RA Weinberg
  • Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy
    HA Kenny, M Lal-Nag, EA White, M Shen, CY Chiang, AK Mitra
  • ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    C Ginestier, MH Hur, E Charafe-Jauffret, F Monville, J Dutcher, M Brown
  • Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
    DW McMillin, J Delmore, E Weisberg, JM Negri, DC Geer, S Klippel
  • Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia
    TW Ridky, JM Chow, DJ Wong, PA Khavari
  • Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors
    V Vaira, G Fedele, S Pyne, E Fasoli, G Zadra, D Bailey
  • Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance
    MM Gerlach, F Merz, G Wichmann, C Kubick, C Wittekind, F Lordick
  • Droplet microfluidic technology for single-cell high-throughput screening
    E Brouzes, M Medkova, N Savenelli, D Marran, M Twardowski, JB Hutchison
  • In vitro 3D models of tumor-immune system interaction
    C Hirt, A Papadimitropoulos, V Mele, MG Muraro, C Mengus, G Iezzi
  • Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness
    LB Weiswald, S Richon, P Validire, M Briffod, R Lai-Kuen, FP Cordelieres
  • Prospective identification of tumorigenic prostate cancer stem cells
    AT Collins, PA Berry, C Hyde, MJ Stower, NJ Maitland
  • Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy
    JA Brockman, S Alanee, AJ Vickers, PT Scardino, DP Wood, AS Kibel
  • Organoid cultures derived from patients with advanced prostate cancer
    D Gao, I Vela, A Sboner, PJ Iaquinta, WR Karthaus, A Gopalan
  • Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
    C Swanton, JM Larkin, M Gerlinger, AC Eklund, M Howell, G Stamp
  • An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
    O Jonas, HM Landry, JE Fuller, JT Santini, J Baselga, RI Tepper
  • A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor
    Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD
  • WSG ADAPT—adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
    D Hofmann, U Nitz, O Gluz, RE Kates, T Schinkoethe, P Staib
  • Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy
    J Montero, KA Sarosiek, JD DeAngelo, O Maertens, J Ryan, D Ercan
  • Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancer
    L Bosserman, K Rogers, C Willis, D Davidson, P Whitworth, M Karimi
  • Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy
    Q Huang, F Li, X Liu, W Li, W Shi, FF Liu
  • Sensitivity, specificity, PPV, and NPV for predictive biomarkers
    R Simon
  • The fundamental difficulty with evaluating the accuracy of biomarkers for guiding treatment
    H Janes, MS Pepe, LM McShane, DJ Sargent, PJ Heagerty
  • On the quantitative assessment of predictive biomarkers
    JP Fine, M Pencina
  • American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays
    HJ Burstein, PB Mangu, MR Somerfield, D Schrag, D Samson, L Holt